Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hep C Cost-Effectiveness Study Supports Limiting Incivek Use

This article was originally published in The Pink Sheet Daily

Executive Summary

Study presented at AASLD provides evidence of the potential value of genotyping patients prior to treatment with new protease inhibitors; Medco ready to start testing program.

You may also be interested in...



Vertex Out To Significant Early Lead In HCV Protease Inhibitor Competition With Merck

Most market analysts predicted Vertex's protease inhibitor would be a bigger seller than Merck's, but a greater than 10-to-1 disparity in third-quarter net sales is still eye-opening.

Telaprevir Labeling Advantages Should Offset Higher Price In Hepatitis C Battle

Vertex Pharmaceuticals' Incivek (telaprevir) has cleared FDA with labeling advantages that should enable it to win a majority of patients in the battle against Merck's competing protease inhibitor for hepatitis C, Victrelis (boceprevir).

With Pradaxa On The Rise, Medco Gathers Evidence On Warfarin Diagnostic Testing

Pharmacy benefits management company Medco Health Solutions Inc. says that with the newly approved oral anticoagulant Pradaxa (dabigatran) off to a good commercial start, it plans to monitor outcomes and compare results with generic warfarin that has been optimized according to genetic testing.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS073018

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel